Long QT syndromes and torsade de pointes

Lancet

Volumn 354, Issue 9190, 1999, Pages 1625-1633

  Viskin, Sami ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ARSENIC; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; CITRIC ACID; DIURETIC AGENT; ERYTHROMYCIN; INOTROPIC AGENT; ISOPRENALINE; MAGNESIUM; MEXILETINE; NEUROLEPTIC AGENT; NICORANDIL; ORGANOPHOSPHATE; POTASSIUM; PRENYLAMINE; PROBUCOL; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SOTALOL; SPIRONOLACTONE; TERODILINE; UNINDEXED DRUG; VASOPRESSIN;

ADOLESCENT; ADULT; AGED; ANOREXIA NERVOSA; BRADYCARDIA; CELIAC DISEASE; CHILD; CLINICAL FEATURE; COMPLETE HEART BLOCK; DISEASE PREDISPOSITION; DRUG TOXICITY; ELECTROCARDIOGRAM; FEMALE; FLUSHING; GASTROPLASTY; GENE MUTATION; GENOTYPE; HEART ARREST; HEART PACING; HEART RATE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INTRAVENOUS DRUG ADMINISTRATION; JEJUNOILEAL BYPASS; LONG QT SYNDROME; MALE; NERVOUS SYSTEM INJURY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; STARVATION; SYNCOPE; TORSADE DES POINTES;

EID: 0033530381     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)02107-8     Document Type: Review

References (78)

1. Roden D.M., Lazzara R., Rosen M., Schwartz P.J., Towbin J., Vincent G.M. Multiple mechanisms in the long QT syndrome: current knowledge, gaps, and future directions. Circulation. 94:1996;1996-2012.
2. Tan H.L., Hou C.J., Lauer M.R., Sung R.J. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med. 122:1995;701-714.
3. Priori S.G., Napolitano C., Cantu F., Schwartz P.J. Differential response to Na+ channel blockade, beta-adrenergic stimulation and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long QT syndrome: experimental basis for gene-specific therapy. Circ Res. 78:1996;1009-1015.
4. + channel opener in the LQT1 form of the congenital long-QT syndrome. Circulation. 97:1998;1581-1588.
5. Compton S.J., Lux R.L., Ramsey M.R.et al. Genetically defined therapy of inherited long QT syndrome: correction of abnormal repolarisation by potassium. Circulation. 94:1996;1018-1022.
6. Abbott G.W., Sesti F., Splawski I.et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 97:1999;175-187.
7. + channel blockade and to increases in heart rate: implications for gene-specific therapy. Circulation. 92:1995;3381-3386.
8. Shimizu W., Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation. 96:1997;2038-2047.
9. Duggal P., Vesely B.S., Wattanasirichaigoon D., Villafane J., Kaushik V., Beggs A.H. Mutation of the gene for IsK associated with both Jervell and Lange Nielsen and Romano-Ward forms of long QT syndrome. Circulation. 97:1998;142-146.
10. Splawski I., Timothy K., Vincent G.M., Atkinson D.L., Keating M.T. Molecular basis of the long QT syndrome associated with deafness. N Engl J Med. 336:1997;1562-1567.
11. Antzelevitch C., Sun Z.Q., Zhang Z.Q., Yan G.X. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol. 28:1996;1836-1848.
12. Vorperian V.R., Zhou Z., Mohammad S., Hoon T.J., Studenik C., January C.T. Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardiol. 28:1996;1556-1561.
13. Zhang Z.H., Boutjdir M., El-Sherif N. Ketanserin inhibits depolarization-activated outward potassium current in rat ventricular myocytes. Circ Res. 75:1994;711-721.
14. Rampe D., Murawsky M., Grau J., Lewis E. The antipsychotic agent sertindole is a high affinity antagonist of human cardiac potassium channel HERG. J Pharmacol Exp Ther. 286:1998;788-793.
15. + current, by the diuretic agent indapamide in guinea pig myocytes. Circ Res. 75:1994;879-886.
16. Drolet B., Khalifa M., Daleau P., Hamelin B.A., Turgeon J. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation. 97:1998;204-210.
17. Zareba W., Moss A.J., Rosero S., Hajj-Ali R., Konecki J., Andrews M. Electrocardiographic findings in patients with diphenhydramine overdose. Am J Cardiol. 80:1997;1168-1173.
18. Bernstein D.I., Shoenwetter W.F., Nathan R.A., Storms W., Ahlbrandt R., Mason J. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 79:1997;443-448.
19. Pinto Y.M., Van-Gelder I.C., Heeringa M., Crijns H.J.G.M. QT lengthening and life-threatening arrhythmias associated with fexofenadine. Lancet. 353:1999;980.
20. Roden D. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. PACE. 21:1998;1029-1034.
21. Jackman W.M., Friday K.J., Anderson J.L., Aliot E.M., Clark M., Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis. 31:1988;115-172.
22. Antzelevitch C., Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations: role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol. 23:1994;259-277.
23. El-Sherif N., Caref E.B., Yin H. The electrophysiological mechanism of ventricular tachyarrhythmias in the long QT syndrome: tridimensional mapping of activation and recovery patterns. Circ Res. 79:1996;474-492.
24. Kay G.N., Plumb V.J., Arciniegas J.G., Henthorn R.W., Waldo A.L. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol. 2:1983;806-817.
25. Locati E.H., Maison-Blanche P., Dejode P., Cauchemez B., Coumel P. Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: quantitative analysis of Holter recordings. J Am Coll Cardiol. 25:1995;1564-1575.
26. Viskin S., Alla S.R., Barron H.V.et al. Mode of onset of torsade de pointes in congenital long QT syndrome. J Am Coll Cardiol. 28:1996;1262-1268.
27. Viskin S., Fish R., Zeltser D.et al. Pause-dependent vs non pause-dependent initiation of torsade de pointes in the congenital long QT syndrome. PACE. 21:1998;II-851. (abstr).
28. Houltz B., Darpo B., Edvardsson N.et al. Electrocardiographic and clinical predictors of torsade de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter. PACE. 21:1998;1044-1057.
29. Tzivoni D., Banai S., Schuger C.et al. Treatment of torsade de pointes with magnesium sulfate. Circulation. 77:1988;392-397.
30. Bailiei D., Inoue H., Kaseda S., Ben-David J., Zipes D. Magnesium suppression of early afterdepolarizations and ventricular tachyarrhythmias induced by cesium in dogs. Circulation. 77:1988;1395-1402.
31. Choy A., Lang C., Chomsky D., Rayos G., Wilson J., Roden D. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation. 97:1997;2149-2154.
32. Yang T., Roden D. Extracellular potassium modulation of drug block of IKr: implicatons for torsades de pointes and reverse use-dependence. Circulation. 93:1996;407-411.
33. Shimizu W., Antzelvitch C. Cellular basis for the ECG features of the LQT1 from of the long QT syndrome: effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation. 98:1998;2314-2322.
34. Nattel S., Quantz M. Pharmacological responses of quinidine induced early afterdepolarizations in canine cardiac Purkinje fibers: insights into underlying ionic mechanisms. Cardiovasc Res. 22:1988;808-817.
35. Shimizu W., McMahon B., Antzelevitch C. Sodium pentobarbital reduces transmural dispersion of repolarization and prevents orsades de pointes in models of acquired and congenital long QT syndrome. J Cardiovasc Electrophysiol. 10:1999;154-164.
36. Zareba W., Moss A.J., Schwartz P.J. Influence of the genotype on the clinical course of the long QT syndrome. N Engl J Med. 339:1998;960-965.
37. 1). J Am Coll Cardiol. 1999; 33: 327-32.
38. Garson A., Dick M., Fournier A.et al. The long QT syndrome in children: an international study of 287 patients. Circulation. 87:1993;1866-1872.
39. Schwartz P.J., Periti M., Malliani A. The long Q-T syndrome. Am Heart J. 89:1975;378-390.
40. Viskin S., Belhassen B. Polymorphic ventricular tachyarrhythmias in the absence of organic heart disease: classification, differential diagnosis and implications for therapy. Prog Cardiovasc Dis. 41:1998;17-34.
41. Moss A.J., Schwartz P.J., Crampton R.S., Locati E.H., Carleen M. The long QT syndrome: a prospective international study. Circulation. 71:1985;17-21.
42. Schwartz P.J., Locati E.H., Moss A., Crampton R., Trazzi R., Ruberti U. Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome: a worldwide report. Circulation. 84:1991;503-511.
43. Eldar M., Griffin J.C., Abbott J.A.et al. Permanent cardiac pacing in patients with the long QT syndrome. J Am Coll Cardiol. 10:1987;600-607.
44. Moss A.J., Liu J.E., Gottlieb S., Locati E.H., Schwartz P.J., Robinson J.L. Efficacy of permanent pacing in the management of high-risk patients with long QT syndrome. Circulation. 84:1991;1524-1529.
45. Viskin S., Fish R., Roth A., Copperman Y. Prevention of torsade de pointes in the congenital long QT syndrome: use of a pause-prevention pacing algorithm. Heart. 79:1998;417-419.
46. Schwartz P.J. The long QT syndrome. Camm J. Clinical approaches to tachyarrhythmias. 1998;1-104 Futura Publishing Company, Armonk, NY.
47. Schwartz P.J. ICD for patients with long QT syndrome. Santini M. Progress in clinical pacing. 1998;Futura Media Service Inc, Armonk, NY.
48. Vincent G.M., Fox J., Zhang L., Timothy K.W. Beta-blockers markedly reduce risk and syncope in KVLQT1 long QT patients. Circulation. 94(suppl I):1996;204. (abstr).
49. Wesley R.C., Turnquest P. Torsade de pointes after intravenous adenosine in the presence of prolonged QT syndrome. Am Heart J. 123:1992;794-796.
50. Kurita T., Ohe T., Marui N.et al. Bradycardia-induced abnormal QT prolongation in patients with complete atrioventricular block with torsades de pointes. Am J Cardiol. 69:1992;628-633.
51. Michaelsson M., Jonzon A., Riesenfeld T. Isolated congenital complete atrioventricular block in adult life: a prospective study. Circulation. 92:1995;442-449.
52. Viskin S., Barron H.V., Olgin J., Heller K., Scheinman M.M. The treatment of atrial fibrillation: pharmacologic and non-pharmacologic strategies. Curr Probl Cardiol. 22:1997;37-108.
53. Krebs M.E., Szwed J.M., Shinn T., Miles W.M., Zipes D.P. Short-term rapid ventricular pacing prolongs ventricular refractoriness in patients. J Cardiovasc Electrophysiol. 9:1998;1036-1042.
54. Prystowsky E.N., Benson W., Fuster V.et al. Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Assocation. Circulation. 93:1996;1262-1267.
55. Makkar R.R., Fromm B.S., Steinman R.T., Meissner M.D., Lehman M.H. Female gender as a risk factor for torsade de pointes associated with cardiovascular drugs. JAMA. 270:1993;2590-2597.
56. Ejvinsson G., Orinius E. Prodromal ventricular premature beats preceded by a diastolic wave. Acta Med Scand. 208:1980;449-450.
57. Maruyama T., Ohe T., Kutia T., Aihara N., Shimizu W. Physiological and pathological responses of TU waves to class 1a antiarrhythmic drugs. Eur Heart J. 16:1995;667-673.
58. Monahan B.P., Ferguson C.L., Killeavy E.S., Lloyd B.K., Troy J., Cantinela L.R. Torsades de pointes occurring in association wth terfenadine use. JAMA. 264:1990;2788-2790.
59. Hanrahan J.P., Choo P.W., Carlson W., Greineder D., Faich G.A., Platt R. Terfenadine-associated ventriciular arrhythmias and QTc interval prolongation: a retrospective cohort comparison with other antihistamines among members of a health maintenance organization. Ann Epidemiol. 5:1995;201-209.
60. Benton R.E., Honig P.K., Zamani K., Cantinela L.R., Woosley R.L. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther. 59:1996;383-388.
61. Wysowski D., Bakanyi J. Cisapride and fatal arrhythmias. N Engl J Med. 335:1996;290-291.
62. Hill S.L., Evangelista J.K., Pizzi A.M., Mobassaleh M., Fulton D.R., Berul C.I. Proarrhythmia associated with cisapride in children. Pediatrics. 101:1998;1053-1056.
63. Cooke R.A., Chambers J.B., Singh R.et al. QT interval in anorexia nervosa. Br Heart J. 72:1994;69-73.
64. Isner J.M., Sours H.E., Paris A.L., Ferrans V.J., Roberts W.C. Sudden, unexplained death in avid dieters using the liquid-protein-modified-fast test: observations in 17 patients and the role of the prolonged QT interval. Circulation. 60:1979;1401-1412.
65. Andreoli A., Pasquale G., Pinelli G., Grazi P., Tognetti F., Testa C. Subarachnoid hemorrhage frequency and severity of cardiac arrhythmias. Stroke. 18:1987;558-564.
66. Chao C.L., Chen W.J., Chung C., Lee Y.T. Torsade de pointes and T-alternans in a patient with brainstem hemorrhage. Int J Cardiol. 51:1995;199-201.
67. Rotem M., Constantini S., Shir Y., Cotev S. Life-threatening torsade de pointes arrhythmia associated with head injury. Neurosurgery. 23:1988;89-92.
68. Grossman M.A. Cardiac arrhythmias in acute central nervous system disease: successful management with stellate ganglion block. Arch Intern Med. 136:1976;203-207.
69. Otteni J., Pettecher T., Bronner C., Flesch H., Diebolt J. Prolongation of the QT interval and sudden cardiac arrest following right radicalneck dissection. Anesthesiology. 59:1983;358-561.
70. Minardo J.D., Heger J.J., Miles W.M., Zipes D.P., Prystowsky E.N. Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. N Engl J Med. 319:1988;257-262.
71. Kurita T., Ohe T., Shimizu W.et al. Early afterdepolarization-like activity in patients with class IA induced long QT syndrome and torsade de pointes. PACE. 20:1997;695-705.
72. Kawasaki R., Machado C., Reinoehl J.et al. Increased propensity of women to develop torsade de pointes during complete heart block. J Cardiovasc Electrophyisol. 6:1995;1032-1038.
73. Vincent G.M., Timothy K.W., Leppert M., Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long QT syndrome. N Engl J Med. 327:1992;846-852.
74. Priori S.G., Napolitano C., Schwartz P.J. Low penetrance in the long-QT syndrome: clinical impact. Circulation. 99:1999;529-533.
75. Priori S.G., Schwartz P.J., Napolitano C.et al. A recessive variant of the Romano-Ward long QT syndrome? Circulation. 97:1998;2420-2425.
76. Donger C., Denjoy I., Berthet M.et al. KVLQT1 C-terminal missense mutation causes a forme fruste long QT syndrome. Circulation. 96:1997;2778-2781.
77. Schulze-Bahr E., Haverkamp W., Hordt M., Wedekind H., Borggrefe M. Do mutations in cardiac ion channel genes predispose to drug-induced (acquired) long QT syndrome? Circulation. 96(suppl I):1977;I-211. (abstr).
78. Napolitano C., Priori S., Schwartz P., Fusco M., Pinnavaia A., Aquaro G. Identification of a long QT syndrome molecular defect in drug-induced torsades de pointes. Circulation. 96(suppl I):1997;I-211. (abstr). A list of further reading on this topic is available on www.thelancet.com.